Cinchona officinalis

Cinchona officinalis is a South American tree bark containing quinine and quinidine alkaloids that exhibit antimalarial, antiviral, and anticancer properties. The bark's quinoline compounds interfere with pathogen replication and cellular proliferation through DNA intercalation and enzyme inhibition.

Origin & History

Cinchona officinalis is a tree native to the Andean regions of South America, particularly Peru and Ecuador, belonging to the Rubiaceae family. The stem bark (known as Peruvian bark or quina-quina) is harvested and processed through percolation or maceration with solvents to extract quinoline alkaloids including quinine, quinidine, cinchonine, and cinchonidine.

Historical & Cultural Context

Cinchona officinalis bark has been used for centuries in South American indigenous medicine, particularly by the Quechua people who called it 'quinas,' to treat fevers including malaria. Introduced to Europe in the 17th century, it became a cornerstone for antimalarial therapy in global traditional medicine systems through bark decoctions.

Health Benefits

• Antiviral activity: Homeopathic preparation showed 89% inhibition of SARS-CoV-2 in VeroE6 cells (PMID: 37673083) - preliminary evidence only
• Anticancer potential: Demonstrated 91% viability inhibition in MCF-7 breast cancer cells at IC50 9 µg/mL (PMID: 36234520) - in vitro evidence only
• Antifungal effects: Bark formulation at 200 µg/mL showed 58-86% growth inhibition reversible by tryptophan - preclinical evidence
• Traditional antimalarial use: Historical application for fever treatment, though no modern clinical trials identified
• Selective cytotoxicity: Showed minimal effects on healthy cells (18% hMSCs) versus cancer cells (91% MCF-7) - preliminary in vitro data

How It Works

Cinchona's primary alkaloids, quinine and quinidine, intercalate with DNA and inhibit topoisomerase enzymes, disrupting cellular replication in pathogens and cancer cells. Quinine specifically interferes with heme polymerization in malaria parasites, causing toxic heme accumulation. The quinoline compounds also modulate ion channels and exhibit anti-inflammatory effects through cyclooxygenase inhibition.

Scientific Research

Current research on Cinchona officinalis is limited to preclinical studies with no human clinical trials, RCTs, or meta-analyses identified. Key studies include in vitro antiviral effects against SARS-CoV-2 (PMID: 37673083) and anticancer activity in MCF-7 cells using nanoparticle formulations (PMID: 36234520/PMC9565860).

Clinical Summary

Clinical evidence is strongest for quinine's antimalarial activity, with decades of proven efficacy against Plasmodium species. Recent in vitro studies show promising antiviral effects, with homeopathic preparations demonstrating 89% SARS-CoV-2 inhibition in cell cultures. Anticancer research remains preliminary, limited to laboratory studies showing 91% viability inhibition in MCF-7 breast cancer cells at 9 µg/mL IC50. Human clinical trials for antiviral and anticancer applications are lacking.

Nutritional Profile

Cinchona officinalis bark is not consumed as a conventional food source and thus lacks a traditional macronutrient profile; its significance lies in its bioactive alkaloid content. Primary alkaloids: quinine (0.3–0.5% dry bark weight), quinidine (0.2–0.4%), cinchonine (0.2–0.5%), and cinchonidine (0.1–0.3%), with total alkaloid content ranging 1.5–7% depending on bark age, geographic origin, and extraction method. Secondary bioactives include quinovic acid glycosides (triterpene saponins), cinchotannic acid (a hydrolyzable tannin, approximately 2–4% dry weight), and quinine red (a degradation product of cinchotannic acid). Flavonoids including quercetin and kaempferol derivatives are present in modest amounts. Mineral content is poorly characterized for this species specifically; bark tannins may reduce bioavailability of divalent cations (iron, zinc) if consumed. Dietary fiber (cellulose and hemicellulose) constitutes the structural matrix of dried bark but is nutritionally incidental. Protein and fat content are negligible in medicinal bark preparations. Bioavailability notes: Quinine is well absorbed orally (bioavailability ~76–88% in humans), undergoes hepatic CYP3A4/CYP2C19 metabolism, with plasma half-life of 8–21 hours; quinidine similarly absorbed but with notable cardiac conduction effects at therapeutic doses. Tannin content may complex with alkaloids and reduce net absorption in whole-bark preparations compared to isolated alkaloid extracts.

Preparation & Dosage

No clinically studied dosage ranges for Cinchona officinalis have been established in human trials. Preclinical studies used variable concentrations: 200 µg/mL for antifungal effects, 9 µg/mL IC50 for anticancer nanoparticles, and homeopathic dilutions for antiviral activity. Consult a healthcare provider before starting any new supplement.

Synergy & Pairings

Artemisia annua, Cat's Claw, Pau d'Arco, Andrographis, Green Tea Extract

Safety & Interactions

Cinchona bark can cause cinchonism at high doses, characterized by tinnitus, headache, nausea, and visual disturbances. Quinine interacts with warfarin, digoxin, and other cardiac medications, potentially causing dangerous arrhythmias. Contraindicated during pregnancy due to uterotonic effects and potential teratogenicity. Individuals with G6PD deficiency should avoid quinine-containing preparations due to hemolysis risk.